Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model by David Ternant, Olivier Le Tilly, Laurence Picon, Driffa Moussata, Christophe Passot, Theodora Bejan-Angoulvant, Céline Desvignes, Denis Mulleman, Philippe Goupille, Gilles Paintaud

Subjects: Get full text

Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study by Hao Liang, Hao Liang, Zhenling Deng, Shu Niu, Weijie Kong, Weijie Kong, Yang Liu, Song Wang, Haiyan Li, Yue Wang, Danxia Zheng, Dongyang Liu, Dongyang Liu, Dongyang Liu

Subjects: Get full text

Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A by Songmao Zheng, Fang Shen, Brian Jones, Damien Fink, Brian Geist, Ivo Nnane, Zhao Zhou, Jeff Hall, Ravi Malaviya, Tatiana Ort, Weirong Wang

Subjects: Get full text

Interleukin 15 Pharmacokinetics and Consumption by a Dynamic Cytokine Sink by John A. Hangasky, Thomas A. Waldmann, Daniel V. Santi

Subjects: Get full text

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease by Kenta Yoshida, Anita Moein, Tobias Bittner, Susanne Ostrowitzki, Helen Lin, Lee Honigberg, Jin Y. Jin, Angelica Quartino

Subjects: Get full text

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins by Liming Liu

Subjects: Get full text

Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent... by Rajbharan Yadav, Siddharth Sukumaran, Tanja S. Zabka, Jinze Li, Amy Oldendorp, Gary Morrow, Arthur Reyes, Melissa Cheu, Jessica Li, Jeffrey J. Wallin, Siao Tsai, Laura Sun, Peiyin Wang, Diego Ellerman, Christoph Spiess, Andy Polson, Eric G. Stefanich, Amrita V. Kamath, Meric A. Ovacik

Subjects: Get full text

A Minimal PBPK/PD Model with Expansion-Enhanced Target-Mediated Drug Disposition to Support a First-in-Human Clinical Study Design for a FLT3L-Fc Molecule by Iraj Hosseini, Brett Fleisher, Jennifer Getz, Jérémie Decalf, Mandy Kwong, Meric Ovacik, Travis W. Bainbridge, Christine Moussion, Gautham K. Rao, Kapil Gadkar, Amrita V. Kamath, Saroja Ramanujan

Subjects: “…expansion-enhanced target-mediated drug disposition (TMDD)…”
Get full text

PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab by Maria Franz, Ravi Kumar Jairam, Lars Kuepfer, Nina Hanke

Subjects: Get full text

Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapy by Rajbharan Yadav, Suzanne Schubbert, Patrick G. Holder, Eugene Y. Chiang, Nargess Kiabi, Liz Bogaert, Irene Leung, Rumana Rashid, Kendra N. Avery, Christine Bonzon, John R. Desjarlais, Shomyseh Sanjabi, Amy Sharma, Michelle Lepherd, Amy Shelton, Pam Chan, Yanqiu Liu, Louis Joslyn, Iraj Hosseini, Eric G. Stefanich, Amrita V. Kamath, Matthew J. Bernett, Vittal Shivva

Subjects: Get full text